KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cme (CME) Total Non-Current Liabilities (2016 - 2025)

Cme (CME) has disclosed Total Non-Current Liabilities for 17 consecutive years, with $169.0 billion as the latest value for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 53.27% to $169.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $169.0 billion, a 53.27% increase, with the full-year FY2025 number at $169.0 billion, up 53.27% from a year prior.
  • Total Non-Current Liabilities was $169.0 billion for Q4 2025 at Cme, up from $158.2 billion in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $177.3 billion in Q1 2022 to a low of $95.0 billion in Q2 2024.
  • A 5-year average of $135.9 billion and a median of $142.1 billion in 2022 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: soared 73.25% in 2021, then crashed 35.29% in 2023.
  • Cme's Total Non-Current Liabilities stood at $168.5 billion in 2021, then fell by 13.07% to $146.5 billion in 2022, then tumbled by 30.25% to $102.2 billion in 2023, then increased by 7.9% to $110.2 billion in 2024, then soared by 53.27% to $169.0 billion in 2025.
  • Per Business Quant, the three most recent readings for CME's Total Non-Current Liabilities are $169.0 billion (Q4 2025), $158.2 billion (Q3 2025), and $151.4 billion (Q2 2025).